2023 NICE 技术鉴定指南:托法替尼治疗活动性强直性脊柱炎【TA920】

2023-10-18 英国国家卫生与临床优化研究所 NICE官网 发表于陕西省

托法替尼(Xeljanz)治疗活动性强直性脊柱炎的循证推荐。

中文标题:

2023 NICE 技术鉴定指南:托法替尼治疗活动性强直性脊柱炎【TA920】

英文标题:

Tofacitinib for treating active ankylosing spondylitis

发布日期:

2023-10-18

简要介绍:

活动性强直性脊柱炎患者不能很好地控制常规治疗通常提供tnf - α抑制剂。如果tnf - α抑制剂不适合或不能很好地控制病情,患者通常提供司库奇尤单抗或伊西贝单抗。托法替尼是司库奇尤单抗或伊西贝单抗的替代品,但对于某些强直性脊柱炎患者可能不那么安全,例如,65岁以上或吸烟的人。

临床试验证据表明,托法替尼治疗活动性强直性脊柱炎比安慰剂更有效。托法替尼尚未与司库奇尤单抗或伊西贝单抗进行直接比较,但间接治疗比较表明其同样有效。

与司库奇尤单抗的成本比较表明,托法替尼具有相似或更低的成本,司库奇尤单抗最有可能在tnf - α抑制剂之后或当它们不适合时使用。因此,如果托法替尼与司库奇尤单抗和伊西贝单抗在同一人群中使用,则推荐使用托法替尼。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2023 NICE 技术鉴定指南:托法替尼治疗活动性强直性脊柱炎【TA920】.pdf)] GetToolGuiderByIdResponse(projectId=1, id=677fb1c003a005cf, title=2023 NICE 技术鉴定指南:托法替尼治疗活动性强直性脊柱炎【TA920】, enTitle=Tofacitinib for treating active ankylosing spondylitis, guiderFrom=NICE官网, authorId=0, author=, summary=托法替尼(Xeljanz)治疗活动性强直性脊柱炎的循证推荐。, cover=https://img.medsci.cn/20221109/1668016299208_4754896.png, journalId=0, articlesId=null, associationId=85, associationName=英国国家卫生与临床优化研究所, associationIntro=英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence)是NHS的组织,设在伦敦和曼彻斯特。NICE成立于1999年4月1日,目标是确保每个英格兰和威尔士人平等享有NHS医疗的机会。NICE制定指南,设定质量标准,管理国家数据库,为NHS、当地权威部门和其他组织提供指南。, copyright=0, guiderPublishedTime=Wed Oct 18 00:00:00 CST 2023, originalUrl=, linkOutUrl=, content=<p>活动性强直性脊柱炎患者不能很好地控制常规治疗通常提供tnf - &alpha;抑制剂。如果tnf - &alpha;抑制剂不适合或不能很好地控制病情,患者通常提供司库奇尤单抗或伊西贝单抗。托法替尼是司库奇尤单抗或伊西贝单抗的替代品,但对于某些强直性脊柱炎患者可能不那么安全,例如,65岁以上或吸烟的人。</p> <p>临床试验证据表明,托法替尼治疗活动性强直性脊柱炎比安慰剂更有效。托法替尼尚未与司库奇尤单抗或伊西贝单抗进行直接比较,但间接治疗比较表明其同样有效。</p> <p>与司库奇尤单抗的成本比较表明,托法替尼具有相似或更低的成本,司库奇尤单抗最有可能在tnf - &alpha;抑制剂之后或当它们不适合时使用。因此,如果托法替尼与司库奇尤单抗和伊西贝单抗在同一人群中使用,则推荐使用托法替尼。</p>, tagList=[TagDto(tagId=19435, tagName=托法替尼), TagDto(tagId=93704, tagName=活动性强直性脊柱炎)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=93704, articleKeyword=活动性强直性脊柱炎, articleKeywordNum=6, guiderKeywordId=93704, guiderKeyword=活动性强直性脊柱炎, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3755, appHits=24, showAppHits=0, pcHits=87, showPcHits=3728, likes=0, shares=6, comments=2, approvalStatus=1, publishedTime=Wed Oct 18 14:50:00 CST 2023, publishedTimeString=2023-10-18, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Wed Oct 18 11:11:30 CST 2023, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 16:08:35 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=陕西省, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2023 NICE 技术鉴定指南:托法替尼治疗活动性强直性脊柱炎【TA920】.pdf)])
2023 NICE 技术鉴定指南:托法替尼治疗活动性强直性脊柱炎【TA920】.pdf
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2163596, encodeId=1713216359610, content=<a href='/topic/show?id=d38b501864f' target=_blank style='color:#2F92EE;'>#强直性脊柱炎#</a> , beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50186, encryptionId=d38b501864f, topicName=强直性脊柱炎)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=litao2022, createdTime=Wed Oct 18 18:14:51 CST 2023, time=2023-10-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163595, encodeId=b4422163595ac, content=<a href='/topic/show?id=e827546e83e' target=_blank style='color:#2F92EE;'>#托法替尼#</a> , beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54678, encryptionId=e827546e83e, topicName=托法替尼)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=litao2022, createdTime=Wed Oct 18 18:14:41 CST 2023, time=2023-10-18, status=1, ipAttribution=上海)]
    2023-10-18 litao2022 来自上海
  2. [GetPortalCommentsPageByObjectIdResponse(id=2163596, encodeId=1713216359610, content=<a href='/topic/show?id=d38b501864f' target=_blank style='color:#2F92EE;'>#强直性脊柱炎#</a> , beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50186, encryptionId=d38b501864f, topicName=强直性脊柱炎)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=litao2022, createdTime=Wed Oct 18 18:14:51 CST 2023, time=2023-10-18, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2163595, encodeId=b4422163595ac, content=<a href='/topic/show?id=e827546e83e' target=_blank style='color:#2F92EE;'>#托法替尼#</a> , beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54678, encryptionId=e827546e83e, topicName=托法替尼)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=litao2022, createdTime=Wed Oct 18 18:14:41 CST 2023, time=2023-10-18, status=1, ipAttribution=上海)]
    2023-10-18 litao2022 来自上海

拓展阅读

礼来的IL-17A单抗Taltz获得FDA批准扩展用于活动性强直性脊柱炎

礼来宣布,FDA已扩大其IL-17A单抗Taltz(ixekizumab)的应用范围,扩展用于治疗患有活动性强直性脊柱炎的成人,也称为射线照相轴性脊柱关节炎。该公司美国免疫学部副总裁丽贝卡o莫里森说:"强直性脊柱炎是一种具有挑战性的疾病,可引起严重的背部疼痛,如果不及时治疗,会严重影响患者的活动能力,"并补充道,"我们很高兴现在提供Taltz用于缓解该类患者的症状。"